Chemical treatment |
DMBA |
hepatoma, cholangiocarcinoma and intestinal cancer |
[30] |
DEN |
hepatoma, cholangiocarcinoma and pancreatic carcinoma |
[23] |
NDMA |
hepatoma and cholangiocarcinoma |
[31] |
ENU |
hepatoma and testicular cancer |
[24] |
MNNG |
hepatoma and testicular cancer |
[32] |
Genetic technology |
Knockout: |
P53
|
malignant peripheral nerve sheath tumors |
[41] |
APC
|
colon adenoma |
[42] |
NF1
|
gliomas and malignant peripheral nerve sheath tumors |
[43] |
BRCA2, MYBL2, esp11
|
testicular cancer |
[44, 45] |
pen/lgl2, bmyb and cds gene
|
epidermal cancer |
[32, 46, 47] |
GSTT1
|
lymphoma |
[48] |
vhl
|
hepatoma and intestinal cancer |
[33] |
pten
|
T-cell acute lymphoblastic leukemia and hemangiosarcoma |
[49, 50] |
Overexpression: |
Myc
|
T-cell leukemia and hepatoma |
[51, 53] |
xmrk and KRAS
(V12)
|
hepatoma |
[52, 54, 55] |
MYCN and fgf8
|
neuroblastoma |
[56] |
KRAS
(G12D)
|
rhabdomyosarcoma |
[57] |
Akt1 |
lipoma |
[58] |
Scr in p53 mutant background
|
hepatoma |
[59] |
NRAS, BRAF in p53 mutant background
|
melanoma |
[60, 41] |
EWS-FIL1 in p53 mutant background
|
Ewing's sarcoma |
[61] |
Xenotransplantation |
Transplant tumor cells in zebrafish |
Melanoma, glioma, hepatoma, lung cancer, pancreatic cancer, ovarian carcinomas, breast cancer, prostate cancer, retinoblastoma, leukemia |
[64–73] |